| Description | This product is a neutralizing antibody that binds to Severe Acute Respiratory Syndrome Coronavirus 2. BD-629 is capable of specifically binding with SARS-CoV-2 and shows a good capacity to neutralize the SARS-CoV-2. |
| Clonality | Monoclonal |
| Host Species | Human |
| Target Species | SARS-CoV-2 |
| Epitope | RBD receptor binding domain |
| Isotype | IgG1 |
| Expression Species | HEK293F or CHO cell line |
| Conjugation | Unconjugated |
| Purity | >95% |
| Endotoxin | <1 EU/mg |
| Form | Liquid |
| Purification | Protein A purified |
| Sterility | 0.2 μM filtered |
| Formulation | PBS, pH 7.4 |
| Preservation | No preservatives |
| Stabilizer | No stabilizers |
| Storage | Store at 4°C within one or two weeks. Store at -20°C for long term. Avoid repeated freeze/thaw cycles. Refer to the COA file for specifics. |
| Application | ELISA |
| Application Notes | ELISA plates were coated with SARS-CoV-2 RBD or S protein at 0.01 μg/mL and 1 μg/mL in PBS at 4°C overnight. After standard washing and blocking, 100 μL 1 μg/mL antibodies was added to each well. After a 2 h incubation at room temperature, plates were washed and incubated with 0.08 μg/mL goat anti-human IgG (H+L)/HRP for 1 h incubation at room temperature. Chromogen solution was used as the substrate, and absorbance at 450 nm was measured by a microplate reader. A mAb is defined as ELISA-positive when the OD450 is saturated using 1 μg/mL RBD/S protein. |
| ELISA | Enzyme-Linked Immunosorbent Assay Protocol |
| WB | Western Blot Protocol |
| FC | Flow Cytometry Protocol |
| Target | SARS-CoV-2 |
| Alternative Name | Severe acute respiratory syndrome coronavirus 2 |
| Research Area | Coronavirus Disease 2019 |
| Related Disease | Coronavirus Disease 2019 |
